Cross Country Healthcare

CCRN · NASDAQ

Price unavailable right now.

No price history for this range.

CCRN analyst rating

HoldConsensus of 5 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold5
Underperform0
Sell0

12-month price target · 8 analysts

Average $12.58

Low: $10.10
High: $13.91

Upgrades and downgrades

The latest rating actions, newest first

CCRN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barrington Research	Jun 8, 2026	Maintains	Market Perform	$13.25	59%
Truist Securities	May 11, 2026	Maintains	Hold	$10.00 → $13.25	61%
Benchmark	May 8, 2026	Downgrade	Buy → Hold	—	51%
Wedbush	May 7, 2026	Downgrade	Outperform → Neutral	$15.00 → $13.25	35%
Wedbush	Mar 19, 2026	Upgrade	Neutral → Outperform	$11.00 → $15.00	35%
Benchmark	Mar 5, 2026	Upgrade	Hold → Buy	$14.00	51%
Wedbush	Feb 3, 2026	Initiates	Neutral	$11.00	35%
UBS	Dec 9, 2025	Maintains	Neutral	$16.50 → $9.00	64%

The case for and against

Updated Jul 25, 2026

Bull case

Cross Country Healthcare is a healthcare workforce solutions company with an AI-powered digital platform and advisory services that help healthcare systems manage their labor ecosystem. Despite a decline in Q1/26 revenue and factors impacting the broader healthcare staffing industry, Cross Country exceeded revenue expectations and reported a 2% sequential increase in revenue led by their Nurse and Allied Staffing segment. However, given their agreement to go private with Knox Lane and the stock price being close to the offer price, maintaining a MARKET PERFORM rating with a price target of $13.25 is recommended. Upside risks include investments in technology leading to margin expansion and potential for a higher bid to emerge, while downside risks include loss of significant MSP customers and impacts from regulations or decreases in patient occupancy. The acquisition deal also highlights the value and potential of Cross Country's AI-powered platform for a financial buyer like Knox Lane.

Bear case

Cross Country Healthcare is facing challenges in retaining clients and generating revenue due to the competitive nature of the healthcare staffing industry and decreased demand for their services during the pandemic. The company's financials have been impacted, with a decrease in revenue and earnings, and there is uncertainty surrounding their ability to recover and grow in the next few years despite their AI-powered digital platform and restructuring initiatives. The recent sale of the company to Knox Lane at a valuation that reflects their current struggles suggests a lack of confidence in their potential future performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.